Leerink Partners Reiterates Buy Rating on Altimmune, Inc.
Leerink Partners reaffirms its optimistic outlook for Altimmune, Inc. with a $10 price target, a 236.56% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on Altimmune, Inc. (ALT) with a $10 price target on June 22, 2026.
- Leerink Partners's $10 price target implies 236.56% upside from Altimmune, Inc.'s ($ALT) current $2.97 share price.
- Altimmune, Inc. traded near $2.95 on Tuesday, with a market cap of about $569.8 million and a 52-week range between $2.56 and $7.73.
- Insiders recently bought shares, and other analysts like HC Wainwright & Co. and Citizens also maintain buy ratings with higher targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Leerink Partners reiterated its buy rating on Altimmune, Inc. (NasdaqGM: ALT) with a price target of $10. Analyst Thomas Smith expressed continued optimism about the company's prospects.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Altimmune, Inc.
Several major institutional investors have shown interest in Altimmune. BlackRock, Inc. increased its holdings by 3,090,979 shares, bringing its total to 12,795,277 shares, valued at approximately $39.4 million. State Street Corp added 2,025,847 shares, now holding 7,145,550 shares worth about $22 million. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both opened new positions, acquiring 5,658,049 and 5,382,002 shares, respectively. Marshall Wace, LLP significantly boosted its stake by 3,095,124 shares, totaling 4,017,901 shares valued at around $12.4 million.
Altimmune, Inc. Stock Down 4.5%
Shares of Altimmune, Inc. traded near $2.95 on Tuesday. The company has a market cap of approximately $569.8 million. Its forward P/E ratio is not meaningful as the company isn't profitable, and it has a beta of 0.234, indicating low volatility. Over the past year, the stock has ranged between $2.56 and $7.73. The 50-day moving average is $2.96, while the 200-day moving average is $3.89. Altimmune maintains a strong liquidity position with a current ratio of 29.56 and a quick ratio of 29.43, alongside a debt-to-equity ratio of 12.62.
$ALT price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Altimmune, Inc.
Several insiders at Altimmune, Inc. made purchases on May 1, 2026. John Gill, Diane Jorkasky, Teri Lawver, Wayne Pisano, Philip Hodges, and Catherine Sohn each bought 48,800 shares. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On June 22, 2026, Leerink Partners reiterated its buy rating for Altimmune, Inc. with a $10 price target. HC Wainwright & Co. maintained its buy rating with a higher target of $20 on May 18, 2026. Citizens also reiterated a buy rating with an $11 target on May 14, 2026. The consensus among nine analysts is a buy recommendation, with an average target price of $16.06.
About Altimmune, Inc.
Altimmune, Inc. is a biotechnology company based in Gaithersburg, Maryland. It focuses on developing treatments for serious liver diseases. Its lead product, pemvidutide, is in Phase 3 trials for various liver-related conditions. Founded in 1997, the company is led by CEO Jerome Benedict Durso and employs 57 people.
Bottom Line
Leerink Partners' reiterated buy rating and $10 target for Altimmune, Inc. reflect ongoing confidence in the company's potential. Investors track these updates as part of analyzing the stock's future trajectory. Remember, analyst ratings are opinions and should be considered in the context of broader research.
Get Altimmune, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.